New Age Alpha Advisors LLC Takes $213,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

New Age Alpha Advisors LLC acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 7,082 shares of the biopharmaceutical company’s stock, valued at approximately $213,000.

Several other institutional investors have also added to or reduced their stakes in TGTX. Vanguard Group Inc. lifted its position in shares of TG Therapeutics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock worth $469,454,000 after purchasing an additional 209,190 shares during the period. State Street Corp lifted its holdings in TG Therapeutics by 35.8% in the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after buying an additional 2,398,015 shares during the period. Charles Schwab Investment Management Inc. boosted its position in TG Therapeutics by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock valued at $38,212,000 after acquiring an additional 84,904 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in TG Therapeutics by 10.5% during the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company’s stock worth $27,797,000 after acquiring an additional 87,679 shares during the period. Finally, Principal Financial Group Inc. raised its position in shares of TG Therapeutics by 7.5% in the 4th quarter. Principal Financial Group Inc. now owns 830,184 shares of the biopharmaceutical company’s stock worth $24,989,000 after acquiring an additional 57,996 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Price Performance

Shares of TGTX opened at $39.82 on Thursday. The business’s fifty day moving average is $34.94 and its 200 day moving average is $30.67. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market cap of $6.25 billion, a P/E ratio of -398.16 and a beta of 2.13.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.